Effects of ivabradine in patients with coronary artery disease and suffering from a reversible contractility dysfunction of the heart muscle
Not Applicable
Completed
- Conditions
- Coronary artery diseaseCirculatory System
- Registration Number
- ISRCTN90566768
- Lead Sponsor
- Institut de Recherches Internationales Servier (France)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
1. Aged 30 to 75 years
2. Male or female
3. Evidence of coronary artery disease proven by clinical history
4. Sinus rhythm and resting heart rate equal or higher than 70 bpm
5. Exercise-inducible myocardial ischaemia
6. Myocardial stunning, assessed by cardiac echocardiography
Exclusion Criteria
1. Angina at rest or angina class IV
2. Unstable cardiovascular condition
3. Previous treament with anti-anginal medication within 1 week before inclusion
4. Significant abnormalities in the laboratory blood evaluation
5. Contra-indication to the administration of ivabradine
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br> 1. Myocardial stunning, by evaluating changes in regional wall motion measuring 2D Strain/Strain rate<br> 2. Measured at selection visit, inclusion visit and end of treatment visit<br>
- Secondary Outcome Measures
Name Time Method <br> 1. Arterial elastance, measured at selection visit, inclusion visit and end of treatment visit<br> 2. Ventricular arterial coupling, measured at selection visit, inclusion visit and end of treatment visit<br> 3. Safety, measured at each visit<br>